Patterns of disease activity in multiple sclerosis patients: A study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups

Journal of Neurology

Volumn 243, Issue 7, 1996, Pages 536-542

  Rovaris, Marco ^a   Barnes, David ^a   Woodrofe, Nicola ^a   Du Boulay, George H ^a   Thorpe, John W ^a   Thompson, Alan J ^a   McDonald, W Ian ^a   Miller, David H ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Cytokines; Gadolinium; Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

CYTOKINE; GADOLINIUM; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS;

ADULT; BRAIN; CYTOKINES; FEMALE; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS;

EID: 0029894358     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00886876     Document Type: Article

References (55)

1. Adachi K, Kumamoto T, Araki S (1990) Elevated soluble interleukin-2 receptor levels in patients with active multiple sclerosis. Ann Neurol 28:687-691
2. Baumhefner RW, Tourtellotte WW, Syndulko K, Waluch V, Ellison GW, Meyers LW, Cohen SN, Osborne M, Shapshak P (1990) Quantitative multiple sclerosis plaque assessment with magnetic resonance imaging. Its correlation with clinical parameters, evoked potentials and intrablood-brain-barrier IgG synthesis. Arch Neurol 47:19-26
3. Benvenuto R, Paroli M, Buttinelli C, Franco A, Barnaba V, Fieschi C, Balsano F (1991) Tumour necrosis factorα synthesis by cerebrospinal-fluid-derived T cell clones from patients with multiple sclerosis. Clin Exp Immunol 84:97-102
4. Capra R, Marciano N, Cotti-Cometti V, Vignolo LA, Bettinzioli M, Airo P, Cattaneo R, Gasparotti R, Moretti R (1992) Immunological and gadolinium-DTPA MRI evaluation of relapsing-remitting multiple sclerosis. Acta Neurol Scand 86:342-345
5. Comi G, Martinelli V, Medaglini S, Locatelli T, Filippi M, Canal N, Triulzi F, Del Maschio A (1989) Correlations between multimodal evoked potentials and magnetic resonance imaging in multiple sclerosis. J Neurol 236:4-8
6. Corti A, Fassina G, Marcucei F, Barbanti E, Cassani G (1992) Oligometric tumour necrosis factor α slowly converts into inactive forms at bioactive levels. Biochem J 284:905-910
7. Corti A, Poiesi C, Merli S, Cassani G (1994) Tumor necrosis factor a quantification by ELISA and bioassay: effects of TNF-α soluble receptor (p55) complex dissociation during assay incubations. J Immunol Methods 177: 191-198
8. Fesenmeier JT, Whitaker JT, Herman PK, Walker DP (1991) Cerebrospinal fluid levels of myelin protein-like material and soluble interleukin-2 receptor in multiple sclerosis. J Neuroimmunol 34:77-80
9. Filippi M, Horsfield MA, Morrissey SP, MacManus DG, Rudge P, McDonald WI, Miller DH (1994) Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 44:635-641
10. Filippi M, Campi A, Martinelli V, Colombo B, Yousry T, Canal N, Scotti G, Comi G (in press) Comparison of triple dose vs standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry
11. Franciotta DM, Grimaldi LME, Martino GV, Piccolo G, Bergamaschi R, Citterio A, Melzi d'Eril GV (1989) Tumour necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol 26: 787-789
12. Frei K, Fredrikson S, Fontana A, Link H (1991) Interleukin-6 is elevated in plasma in multiple sclerosis. J Neuroimmunol 31:147-153
13. Gallo P, Piccinno MG, Pagni S, Argentiero V, Giometto B, Bozza F, Tavolato B (1989) Immune activation in multiple sclerosis: study of IL-2, sIL-2R and γ-IFN levels in serum and cerebrospinal fluid. J Neurol Sci 92:9-15
14. Hartung HP, Reiners K, Archelos JJ, Michels M, Seeldrayers P, Heidenreich F, Pflughaupt KW, Toyka KV (1995) Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann Neurol 38: 186-193
15. Hauser SL, Doolittle TH, Lincoln R, Brown RH, Dinarello CA (1990) Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology 40:1735-1739
16. Hawkins CP, Munro PMG, MacKenzie F, Kesselring G, Tofts PS, duBoulay EPGH, Landon DN, McDonald WI (1990) Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental encephalomyelitis studied by gadolinium-DTPA and protein markers. Brain 113: 365-378
17. Imamura K, Suzumura A, Hayashi F, Marunouchi T (1993) Cytokine production by peripheral blood monocytes/macrophages in multiple sclerosis patients. Acta Neurol Scand 87:281-285
18. Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF (1993) Correlation between magnetic resonance imaging and lesion development in chronic active multiple sclerosis. Ann Neurol 34:661-669
19. Kermode AG, Thompson AJ, MacManus DG, Kendall BE, Kingsley DPE, Moseley IF, Rudge P, McDonald WI (1990) Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis: pathogenetic and clinical implications. Brain 113:1477-1489
20. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 33:1444-1452
21. Maimone D, Gregory S, Arnason BG, Reder AT (1991) Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol 32:67-74
22. 2+ influx in T-lymphocytes from multiple sclerosis patients. Proc Natl Acad Sci USA 91:4825-4829
23. McCarron RM, Wang L, Racke MK, et al (1993) Cytokine-regulated adhesion between encephalitogenic T lymphocytes and cerebrovascular endothelial cells. J Neuroimmunol 43:23-30
24. Merrill JE (1992) Proinflammatory and antiinflammatory cytokines in multiple sclerosis and central nervous system acquired immunodeficiency syndrome. J Immunother 12:167-170
25. Miller DH, Rudge P, Johnson G, Kendall BE, MacManus DG, Moseley IF, Barnes D, McDonald WI (1988) Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 111:927-939
26. Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ (1991) Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry 54:683-688
27. Miller DH, Barkhof F, Nauta JJP (1993) Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 116:1077-1094
28. Nesbit GM, Forbes GS, Scheithauer BW, Okazaki H, Rodriguez M (1991) Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology 180:467-474
29. Olsson T (1994) Role of cytokines in multiple sclerosis and experimental immune encephalomyelitis. Eur J Neurol 1:7-19
30. Ormerod IEC, Miller DH, McDonald WI, duBoulay EPGH, Rudge P, Kendall BE, Moseley IF, Johnson G, Tofts PS, Halliday AM, Bronstein AM, Scaravilli F, Harding AE, Barnes D, Zilkha KJ (1987) The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain 110: 1579-1616
31. Palo J, Ketonen L, Wikstrom M (1988) A follow-up study of very low field MRI findings and clinical course in multiple sclerosis. J Neurol Sci 84: 177-187
32. Panitch HS, Hirsch RL, Schindler L, Johnson KP (1987) Treatment of multiple sclerosis with gamma Interferon: exacerbations associated with activation of immune system. Neurology 37: 1097-1103
33. Peter JB, Boctor FN, Tourtellotte WW (1991) Serum and CSF levels of IL-2, s-IL-2R, TNF-α, and IL-1 β in chronic-progressive multiple sclerosis: expected lack of clinical utility. Neurology 41:121-123
34. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227-231
35. Raine CS (1994) McFarlin Memorial Lecture: the immunology of the multiple sclerosis lesion. Ann Neurol 36 [Suppl]: S61-S72
36. Raine CS (1995) Multiple sclerosis: TNF revisited, with promise. Nature Med 1:211-214
37. Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI (1994) A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 117:759-765
38. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, Luer W, Poser S (1994) Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology 44:1523-1526
39. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, Luer W, Helwig A, Poser S (1995) Tumor necrosis factor-α messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 37: 82-88
40. Rodriguez M, Scheitauer BW, Forbes G, Kelly PJ (1993) Oligodendrocyte injury is an early event in lesions of multiple sclerosis. Mayo Clin Proc 68: 627-636
41. Selmaj KW, Raine CS (1988) Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 23:339-346
42. Sharief MK, Hentges R (1991) Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N Engl J Med 325:467-472
43. Sharief MK, Thompson EJ (1992) In vivo relationship of tumor necrosis factor-α to blood-brain barrier damage in patients with active multiple sclerosis. J Neuroimmunol 38:27-33
44. Sharief MK, Hentges R, Ciardi M, Thompson EJ (1993) In vivo relationship of interleukin-2 and soluble IL-2 receptor to blood-brain barrier impairment in patients with active multiple sclerosis. J Neurol 240:46-50
45. Shaw CE, Dumbar PR, Macaulay HA, Neale TJ (1995) Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol 242:53-58
46. Sommer N, Loschmann PA, Northoff GH, Weller M, Steinbrecher A, Steinbach JP, Lichtenfels R, Meyermann R, Riethmuller A, Fontana A, Dichgans J, Martin R (1995) The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Med 1:244-248
47. The IFNB MS Study Group and the UBC MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45:1277-1285
48. Thompson AJ, Kermode AG, Wicks D, MacManus DG, Kendall BE, Kingsley DPE, McDonald WI (1991) Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 29:53-62
49. Thompson AJ, Miller DH, Youl B, MacManus DG, Moore S, Kingsley D, Kendall B, Feinstein A, McDonald WI (1992) Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 42:60-63
50. Trotter JL, Collins KG, Veen RC van der (1991) Serum cytokine levels in chronic progressive multiple sclerosis: IL-2 levels parallel TNF-α levels. J Neuroimmunol 33:29-36
51. Truyen L, Gheuens J, Van de Vyver FL, Parizel PM, Peersman GV, Martin J-J (1990) Improved correlation of magnetic resonance imaging with clinical status in multiple sclerosis by use of an extensive standardized imaging-protocol. J Neurol Sci 96:173-182
52. Tsukada N, Miyagi K, Matsuda M, Yanagisawa N, Yone K (1991) Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J Neurol Sci 102:230-234
53. Woodrofe MN, Cuzner ML (1993) Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. Cytokine 5:583-588
54. Wucherpfennig KW, Newcombe J, Li H, Keddy C, Cuzner ML, Hafler DA (1992) T cell receptor Va-Vb repertoire and cytokine gene expression in active multiple sclerosis lesions. J Exp Med 175:993-1002
55. Zoukos Y, Kidd D, Woodrofe MN, Kendall BE, Thompson AJ, Cuzner ML (1994) Increased expression of high affinity IL-2 receptors and b-adrenoceptors on peripheral blood mononuclear cells is associated with clinical and MRI activity in multiple sclerosis. Brain 117:307-315